COMPARATIVE EFFICIENCY OF NEOBUTINE® RETARD, FILM-COATED PROLONGED-RELEASE TABLETS 300 MG, AND TRIMEDAT®, TABLETS 200MG, IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

In a randomized clinical trial involving 60 patients with irritable bowel syndrome (IBS), a comparison of the efficacy and safety of the use of Neobutine® Retard (film-coated prolonged- release tablets 300 mg, manufactured by AO FP «Obolenskoe»), and Trimedat® tablets 200 mg (manufactured by OAO «Valenta Pharmaceutics», Russia) was performed. The objectives of the study also included an assessment of the quality of life of patients and the compliance with treatment in comparison with the variants of treatment of IBS. Administration of Neobutine® Retard 300 mg and Trimedate® 200 mg lead to significant and comparable positive clinical effects for the relief of IBS symptoms. It is shown that therapy with trmebutine preparations (opioid receptor agonists) significantly improves the quality of life of patients and leads to a reduction in the time of achieving remission of IBS. The recommended regimen of treatment with Neobutine® Retard (300 mg twice a day) is superior to the traditional regimen of treatment with Trimedat® (200 mg 3 times a day).

irritable bowel syndrome, opioid receptors, trimebutine, Neobutine Retard, Trimedate, quality of life, compliance with treatment